Latin America Hemato Oncology Testing Market Size & Outlook

The hemato oncology testing market in Latin America is expected to reach a projected revenue of US$ 737.6 million by 2028. A compound annual growth rate of 12.8% is expected of Latin America hemato oncology testing market from 2021 to 2028.

Revenue, 2020 (US$M)
$282.0
Forecast, 2028 (US$M)
$737.6
CAGR, 2021 - 2028
12.8%
Report Coverage
Latin America

Latin America hemato oncology testing market highlights

  • The Latin America hemato oncology testing market generated a revenue of USD 282.0 million in 2020.
  • The market is expected to grow at a CAGR of 12.8% from 2021 to 2028.
  • In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
  • Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.
  • Country-wise, Mexico is expected to register the highest CAGR from 2021 to 2028.


Latin America data book summary

Market revenue in 2020USD 282.0 million
Market revenue in 2028USD 737.6 million
Growth rate12.8% (CAGR from 2020 to 2028)
Largest segmentLymphoma
Fastest growing segmentLymphoma
Historical data covered2018 - 2019
Base year for estimation2020
Forecast period covered2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationLeukemia, Lymphoma, MPNs, Other Cancers
Key market players worldwideRoche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, Latin America region accounted for 12.1% of the global hemato oncology testing market in 2020.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2028.
  • North America is the fastest growing regional market and is projected to reach USD 2,516.4 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemato Oncology Testing Market Scope

Hemato oncology testing market segmentation & scope
AML
ALL
CLL
CML
NHL
HL
PV
ET
MF
Other Cancers
Assay Kits and Reagents
Services
PCR
Real-time qPCR
Digital PCR
IHC
NGS
Cytogenetics
Others
Hospitals
Academic & Research Institutes
Others

Hemato Oncology Testing Market Companies

Name Profile # Employees HQ Website

Latin America hemato oncology testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.


Lymphoma was the largest segment with a revenue share of 45.89% in 2020. Horizon Databook has segmented the Latin America hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.


The Latin America market is majorly driven by Brazil, Mexico, and Argentina. Growing investments by market players in the region, proximity to North America, high prevalence of blood cancer, and freetrade agreements with major countries are anticipated to boost the Latin American hemato-oncology testing market during the forecast period.

Reasons to subscribe to Latin America hemato oncology testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Latin America hemato oncology testing market databook

  • Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America hemato oncology testing market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Latin America hemato oncology testing market size, by country, 2018-2028 (US$M)

Latin America Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)

Latin America hemato oncology testing market size, by country, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more